Welcome to our dedicated page for ACME UNITED SEC filings (Ticker: ACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acme United Corporation filings document the formal disclosures of an operating company that supplies first aid and medical products, safety solutions and cutting technology. Its 8-K reports include operating and financial results, material-event disclosures, acquisition-related reporting, credit-facility matters and other corporate updates affecting the company's capital and operating structure.
ACU proxy and annual-meeting filings cover board elections, executive compensation votes, equity incentive plan amendments and auditor ratification. The company's regulatory record also includes material agreement disclosures, including amendments to its secured revolving credit facility, along with governance matters and shareholder voting results.
Acme United Corporation reported higher sales but lower profits for the quarter ended March 31, 2026. Net sales rose to $52.3 million from $46.0 million a year earlier, a 14% increase, or 6% growth excluding the My Medic acquisition.
Net income declined to $1.0 million, or $0.24 per diluted share, from $1.7 million, or $0.41 per diluted share, as higher cost of sales and operating expenses offset revenue gains. The company cited tariff-related costs, enhanced quality assurance spending at the Med-Nap facility, and rising employee healthcare costs as key drivers.
Acme highlighted contributions from the recently acquired My Medic business, which has annual sales of $19 million but minimal first-quarter profit due to seasonality. U.S., European, and Canadian segments all posted double-digit sales growth in U.S. dollars. Bank debt less cash increased to $38.6 million, reflecting the My Medic acquisition, a German product line purchase, dividends, a new Tennessee facility, and inventory builds to mitigate supply risks from the conflict in Iran.
Acme United Corporation had a Schedule 13G/A amendment reporting that The Capital Management Corporation beneficially owned 500,967.30 shares of Common stock, representing 13.2% of the class as of 03/31/2026. The filing states sole voting power of 496,192.30 shares and sole dispositive power of 500,967.30 shares. The filing was signed by Pamela Simms as Compliance Officer on 04/02/2026.
Acme United Corporation is asking shareholders to vote at a virtual 2026 annual meeting on April 27, 2026 at 11:00 a.m. Eastern via www.virtualshareholdermeeting.com/ACU2026. Shareholders of record on March 10, 2026, when 3,808,225 common shares were outstanding, may vote online, by phone, mail or during the meeting.
Seven incumbent directors are nominated for one-year terms, including Chairman and CEO Walter C. Johnsen and President and COO Brian S. Olschan. Shareholders are also asked to approve an amendment to the 2022 Employee Stock Option Plan, increasing the shares reserved for options from 500,000 to 700,000, an advisory say-on-pay resolution for named executive officers, and ratification of CBIZ CPAs, P.C. as independent auditor for 2026.
Directors and executive officers as a group beneficially own 1,196,551 shares, or 29.5% of the common stock. In 2025, total compensation was $1,669,401 for CEO Walter C. Johnsen, $1,397,357 for President and COO Brian S. Olschan, and $928,724 for CFO Paul G. Driscoll, including salary, bonuses and stock option awards.
Acme United Corporation reported modest growth for 2025, with net sales of $196.5 million, up 1% from 2024, and net income of $10.2 million. Gross margin held steady at 39.4%, while operating income rose slightly to $14.7 million as first aid and medical products drove performance.
The company continued shifting toward healthcare, with first aid and medical products reaching about 66% of sales and the Elite First Aid and My Medic businesses expanding its trauma and emergency response portfolio. Bank debt was reduced, leaving $53.1 million available under a $65 million credit facility, supporting acquisitions, dividends, and growth investments.
ACME United Corp director Susan H. Murphy reported a bona fide gift of 1,200 shares of common stock on March 3, 2026. The gift transaction was recorded at $44.08 per share. After this disposition, she directly holds 5,967 common shares of ACME United.
ACME United Corp Chief Financial Officer Paul G. Driscoll reported option awards and related transactions in company stock. On March 2, 2026, he received an employee stock option for 15,000 shares at an exercise price of $44.77 per share. According to the vesting schedule, 3,750 option shares will vest on each of March 2, 2027, March 2, 2028, March 2, 2029, and March 2, 2030.
On February 27, 2026, Driscoll exercised 15,000 employee stock options at $21.49 per share and simultaneously disposed of 15,000 shares of common stock to the issuer at $45.88 per share. The option exercise was effected on a net cash settlement basis directly with the company, without the actual issuance of any new shares of underlying common stock. After these transactions, he held 50,398 shares of common stock directly.
ACME UNITED CORP director and President/COO Brian S. Olschann reported option and stock transactions. He received a grant of 20,000 employee stock options at $44.77 per share, with 5,000 options vesting annually from March 2, 2027 through March 2, 2030. He also exercised 15,000 options at $24.92 per share into 15,000 shares of common stock and, in a related transaction with the issuer, disposed of 15,000 common shares at $45.88 per share via a net cash settlement that did not involve issuing new shares.
ACME United Corp director and CEO Walter C. Johnsen reported multiple equity compensation transactions. On March 2, 2026, he received a grant of 25,000 employee stock options at an exercise price of $44.77 per share. According to a footnote, 6,250 options vest on each of March 2, 2027, 2028, 2029, and 2030.
On February 27, 2026, he exercised 30,000 employee stock options at $21.49 per share and acquired 30,000 shares of common stock through this derivative exercise. The same day, he disposed of 30,000 common shares to the issuer at $45.88 per share. A footnote states this option exercise was settled on a net cash basis directly with the issuer and did not involve the actual issuance of any underlying common shares.
Acme United Corporation reported modest sales growth but stronger earnings for 2025 and the fourth quarter. Net sales for Q4 2025 rose to $47.5 million from $45.9 million, while net income increased to $1.9 million, or $0.46 per diluted share, up 12% per share from 2024.
For the full year 2025, net sales edged up to $196.5 million from $194.5 million. Net income was $10.2 million, or $2.49 per diluted share, slightly above 2024. The company highlighted tariff-related uncertainty that hurt some U.S. retail promotions but noted strong first aid product sales, robust growth in Europe and Canada, and stable gross margins.
Acme acquired My Medic in January 2026, a tactical and emergency response products business with approximately $19 million in 2025 revenues for a purchase price of $18.7 million. Bank debt less cash fell to $18.1 million as of December 31, 2025, helped by about $13.6 million in free cash flow and investment in a new $6 million Tennessee facility.